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Abstract
Surfactant proteins (SP) have been studied intensively in the respiratory system. Surfactant protein A and surfactant protein
D are proteins belonging to the family of collectins each playing a major role in the innate immune system. The ability of
surfactant protein A and surfactant protein D to bind various pathogens and facilitate their elimination has been described
in a vast number of studies. Surfactant proteins are very important in modulating the host’s inflammatory response and
participate in the clearance of apoptotic cells. Surfactant protein B and surfactant protein C are proteins responsible for
lowering the surface tension in the lungs. The aim of this study was an investigation of expression of surfactant proteins in
the central nervous system to assess their specific distribution patterns. The second aim was to quantify surfactant proteins
in cerebrospinal fluid of healthy subjects compared to patients suffering from different neuropathologies. The expression of
mRNA for the surfactant proteins was analyzed with RT-PCR done with samples from different parts of the human brain. The
production of the surfactant proteins in the brain was verified using immunohistochemistry and Western blot. The
concentrations of the surfactant proteins in cerebrospinal fluid from healthy subjects and patients suffering from
neuropathologic conditions were quantified using ELISA. Our results revealed that surfactant proteins are present in the
central nervous system and that the concentrations of one or more surfactant proteins in healthy subjects differed
significantly from those of patients affected by central autoimmune processes, CNS infections or cerebral infarction. Based
on the localization of the surfactant proteins in the brain, their different levels in normal versus pathologic samples of
cerebrospinal fluid and their well-known functions in the lungs, it appears that the surfactant proteins may play roles in host
defense of the brain, facilitation of cerebrospinal fluid secretion and maintenance of the latter’s rheological properties.
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Introduction
The healthy central nervous system has conventionally been
considered to be almost completely independent of the immune
system [1]. Interactions of the two systems were assumed to occur
only under pathological conditions [2]. In recent years this
absolute ‘immune privilege’ of the CNS has been reconsidered and
a distinct network of brain specific defense- and regulatory
mechanisms has been unveiled [3,4].
In general, the blood-brain barrier (BBB) and the blood-
cerebrospinal fluid barrier (BCSFB) limit the access of cells and
proteins circulating in the bloodstream to the brain [5]. The
restricted entry of peripherally produced cells and molecules
necessitates an efficient system in the brain capable of recognizing
and eliminating pathogens, apoptotic cells and detrimental
metabolic products. Astrocytes and microglia are both cellular
players that monitor the brain continuously and react rapidly in
case of pathological changes [6,7]. Besides these brain-specific
effector cells, many molecular factors in the innate immune
system, e.g. complement factors [8] and defensins [9], have been
shown to be important components of the CNS.
Surfactant proteins are part of the pulmonary surfactant, a thin
layer covering the alveolar surface, decreasing the surface tension
between the air and the alveoli of the lungs to prevent the collapse
of the small airways at the end of expiration. The pulmonary
surfactant consists of lipids, mainly phosphatidylcholine and
phosphatidylglycerol, and surfactant proteins A, B, C and D.
The proteins are essential for the proper function of the surfactant
and can be divided into two major structural and as a consequence
functional groups.
Surfactant protein A (SP-A) and surfactant protein D (SP-D) are
molecular factors of the innate immune system; they facilitate the
elimination of numerous pathogens in the lungs. For example,
they promote phagocytosis of Mycobacterium tuberculosis by alveolar
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the invading pathogen [10]. While SP-A is upregulated in human
alveolar epithelial cells after LPS exposure [11], SP-D mediates
phagocytosis of Pseudomonas aeruginosa, Haemophilus influenzae and
Klebsiella pneumoniae [12,13,14]. SP-A and SP-D are also part of the
first line of defense against viral and fungal invaders [15,16].
Recent studies also showed their involvement in recognition and
clearance of apoptotic cells [17].
Surfactant protein B (SP-B) and surfactant protein C (SP-C) are
small hydrophobic proteins with the main function of decreasing
surface tension at the air-liquid interface in distal airways [18].
They interact with phospholipids (mainly dipalmitoylphosphati-
dylcholine) and enable the adsorption of lipids and their
distribution at the air-liquid interface [19]. Furthermore, they
are able to render phospholipid membranes highly permeable to
polar molecules and are assumed to form proteolipid pores in
biomembranes [20]. SP-B also has anti-inflammatory properties:
Ikegami et al. showed that SP-B deficiency leads to an increase of
proinflammatory cells, total protein and proinflammatory cyto-
kines in the bronchioalveolar fluid of transgenic mice. Restoration
of SP-B expression rapidly reversed the described signs of
inflammation [21]. Besides its anti-inflammatory abilities, SP-B
has bactericidal (Staphylococcus aureus, Klebsiella pneumoniae) and
bacteriostatic (Pseudomonas aeruginosa) effects [22].
SP-C binds bacterial lipopolysaccharide (LPS) and modifies pro-
inflammatory cytokine-mRNA in monocytes after LPS stimulation
[23,24].
Extra-pulmonary production of SPs and their importance for
host defense and maintenance of physiological conditions has been
demonstrated in a number of tissues and organs amongst them the
salivary system [25,26], the ocular surface [27,28] as well as the
nasal cavity [29].
Considering the specific localization of SPs at anatomical–
physiological barriers (e.g., the air-tissue interface in the airways)
and their importance as innate defense molecules, we hypothe-
sized that the four known surfactant proteins are molecular
components of the innate immune system of the CNS. We
particularly assumed their role as pathogen-binding proteins at the
barriers between blood and CNS, protecting the highly vulnerable
tissue from bacteria, viruses and fungi circulating in the
bloodstream.
In addition, regarding the known effects of SPs on biological
fluids, we proposed the presence of SPs in cerebrospinal fluid,
acting as regulators of its rheological properties.
Materials and Methods
The study was conducted in compliance with Institutional
Review Board regulations, informed consent regulations, and the
provisions of the Declaration of Helsinki.
Tissue
Because of the origin of tissue samples and the background of
acquisition of csf samples no ethics committee approval was
necessary.
The brain samples were obtained from body donors (3 female, 4
male, aged 54–77 years) at the Institute for Anatomy and Cell
Biology Halle-Wittenberg, Germany. Prior to death every body
donor dedicated his body to the Institute for Anatomy and Cell
Biology for scientific and academic purposes, stating this in his last
will. Tissue samples were anonymized. All tissues used were
dissected from the cadavers within 9–24 hours post mortem. Prior
to dissection, the medical history of each body donor was studied
and donors with neurological syndromes were excluded. The brain
of each cadaver was sagitally split in half. One half was fixed in 4%
paraformaldehyde, the other half was further dissected and the
regions of interests (cortex, brainstem, choroid plexus, meninges,
cerebellum, optic nerve, pineal gland, pituitary gland) were
immediately snap-frozen in liquid nitrogen and stored at 280uC
for further biomolecular investigation.
Cerebrospinal fluid (CSF)
Samples of cerebrospinal fluid (n=118; 50 female, 68 male)
were generously donated by the Institute of Medical Microbiology,
Martin-Luther-University, Halle/Wittenberg. The samples were
collected for routine medical diagnostics to confirm or disprove
CNS-infections and the remnants were stored over years at
280uC for possible further testing. Informed consent was written
for the lumbar puncture and the acquisition of cerebrospinal fluid.
After the death of the patient the related CSF sample was
approved for scientific purposes and released to the Institute for
Anatomy and Cell Biology together with the information about
gender and diagnoses of the patients. The CSF samples were
anonymized. Samples of cerebrospinal fluid from patients with
stroke (ischemic or hemorrhagic infarction of the brain), autoim-
mune inflammation of the CNS (multiple sclerosis, acute
disseminating encephalomyelitis, neuromyelitisoptica) and infec-
tions of the CNS were included in the study. In order to sustain
comprehensibility of the underlying cause for the alteration of SP
concentrations in the CSF, the following specimens were excluded:
CSF samples with blood contamination, CSF samples from
patients with stroke/cerebral infarction plus evidence of bacterial
growth, CSF samples from patients with hemorrhage into the
subarachnoid space and CSF samples from patients without a
diagnosed CNS illness but with a laboratory ascertained elevated
CSF/serum albumin ratio, indicating a disturbance of the blood-
cerebrospinal fluid barrier.
Preparation of RNA and synthesis of complementary
DNA (cDNA)
For reverse transcriptase polymerase chain reaction (RT-PCR),
tissue samples from 5 different regions of the 7 donor brains were
crushed in an agate mortar under liquid nitrogen and homoge-
nized in 5 ml PeqGold RNA pure solution (PeqLab Biotechno-
logie, Erlangen, Germany) with a Polytron homogenizer. The CSF
samples were treated under the same conditions except for
crushing under liquid nitrogen. Insoluble material was removed by
centrifugation (12.000 g, 5 min, 4uC). Total RNA was isolated
using RNeasy-Kit (Qiagen, Hilden, Germany). Crude RNA was
purified with isopropanol and repeated ethanol precipitation.
Contaminating DNA was destroyed by digestion with RNase-free
DNase I (20 min 25uC; Boehringer, Mannheim, Germany). The
DNAse was heat-denatured for 15 min at 65uC. 500 ng RNA
were used for each reaction: cDNA was generated with 50 ng/ml
(20 pmol) oligo (dT)15 primer (Amersham Pharmacia Biotech,
Uppsala, Sweden) and 0.8 ml superscript RNase H
2 reverse
transcriptase (100 U; Gibco, Paisley, UK) for 60 min at 37uC. The
ubiquitously expressed b-actin, which proved amplifiable in each
case with the specific primer pair, served as the internal control for
the integrity of the transcribed cDNA.
PCR – polymerase chain reaction
For conventional PCR, 1 ml cDNA from each sample was
incubated with 13.7 mlH 2O, 1 ml 50 mM MgCl2, 0.5 ml dNTPs,
2 ml 10x PCR buffer, 0.3 ml (5 U) Taq DNA polymerase
(Invitrogen) and 0.5 ml (100 pmol) of each of the following primers
(displayed in table 1).
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consisted of (1) 96uC for 60 s, (2) 57uC (SP-A, SP-B, SP-C, and SP-
D) for 60 s each, (3) 72uC for 60 s. 35 cycles were performed with
each primer pair. The final elongation cycle consisted of 72uC for
4 min. The primers were synthesized by MWG-Biotech AG,
Ebersberg, Germany. 10 ml of the PCR product solution was
loaded on an agarose gel and after electrophoresis the amplified
products were visualized via fluorescence. Base pair (bp) size values
were compared with gene bank data. For verification and
comparison, plasmids containing the open reading frame for the
corresponding protein were used as a reference (German Resource
Centre for Genome Research GmbH; SP-A: IR-
AUp969H0686D6; SP-B: IRAKp961K1368Q2, SP-C:
IKAUp969F0244D6, SP-D: IRAUp969D0386D6). PCR products
were also confirmed by BigDye sequencing (Applied Biosystems,
Foster City, CA). To estimate the amount of amplified PCR
product, we performed a b-actin PCR with specific primers
(table 1) for each investigated tissue. This additional PCR was
performed under the above-mentioned conditions. 10 ml of the
PCR product were loaded on the agarose gel. The base pair
marker (MassRuler DNA-Ladder, Fermentas, St. Leon-Rot,
Germany) used for each PCR ranges from 80 to 1,031 bp.
Antibodies
Antibodies (displayed in table 2 and 3) were used for Western
blot analysis as well as for immunohistochemical investigations as
specified by the manufacturer.
Western blot
Tissue samples (n=4; 2 male, 2 female) of brainstem (BS),
cerebellum (Ce), choroid plexus (CP), the circle of Willis (CW),
subventricular cortex (Ve), pia mater (PM) from body donors were
homogenized in RIPA buffer (20–188, Chemicon-Millipore) on ice
with a tissue homogenizer (IKA T 10 Basic Ultra Turrax
Homogenizer, Cole Parmer). Generally, 100 mg of each tissue
sample was submerged in 300 ml of RIPA buffer. After homog-
enization the samples were incubated for 2 hours on ice and
subsequently spun down at 21000 g for 20 min. The supernatant
containing the proteins was used for further analysis. Two native
CSF samples were used for Western blotting without prior protein
isolation. The protein concentration of these samples was
determined with a protein assay based on the Bradford dye-
binding procedure (BioRad, Hercules, CA). For SDS-PAGE, each
well of a 15% Tris-HCL gel was loaded with 40 mg of total
protein. Protein isolate from human lung tissue served as positive
control. After separating the proteins in the gel under reducing
conditions, the proteins were transferred electrophoretically onto
nitrocellulose membranes. Unspecific binding of the primary
antibody was prevented using 5% milk in PBS as blocking solution
for 1 hour at room temperature. The blocking solution was
Table 1. Sequences of the primers used for detection of surfactant proteins (A; B; C; D), RT-PCR analysis.
Primer Sense primer, 59 R 39 Antisense primer, 59 R39 bp 6C
SP-A CTG TCC CAA GGA ATC CAG AG CCG TCT GAG TAG CGG AAG TC 120 57
SP-B CAC CAT GTT CCC CAT TCC TCT TCA TCC ATG GAG CAC CGG AGG ACG 239 57
SP-C CTG GTT ACC ACT GCC ACC TT TCA AGA CTG GGG ATG CTC TC 142 57
SP-D AGG AGC AAA GGG AGA AAG TGG G CAG CTG TGC CTC CGT AAA TGG 199 57
Gyrase A TGT GCT TTA TGC CAT GAG CGA TCC ACC GAA CCG AAG TTG C 220 58
b-Actin CAA GAG ATG GCC ACG GCT GCT TCC TTC TGC ATC CTG TCG GCA 275 60
doi:10.1371/journal.pone.0074412.t001
Table 2. Molecular weights of the surfactant proteins and specific antibodies used for their detection in Western blot analysis and
immunohistochemistry.
Protein Molecular weight (kDa) Antibody Company, catalog number
SP-A*
1 28–36; 66 Mouse monoclonal anti human SP-A Millipore; MAB3270
SP-A*
2 28–36; 66 Goat polyclonal anti human SP-A Santa Cruz; sc-7699
SP-B*
3 8; 18; 40 Goat polyclonal anti human SP-B Santa Cruz; sc-7701
SP-B*
4 8; 18; 40 Mouse monoclonal anti human SP-B Millipore; MAB3276
SP-C*
5 4–6; 6–12; 21; 26 Rabbit polyclonal anti human SP-C Chemicon; AB3786
SP-D*
6 43 Rabbit polyclonal anti human SP-D Chemicon; AB3434
SP-D*
7 43 Rabbit polyclonal anti human SP-D Santa Cruz; sc-7708
doi:10.1371/journal.pone.0074412.t002
Table 3. Specific secondary antibodies used for their
detection in Western blot analysis and
immunohistochemistry.
Antibody Company, Catalog number
Anti-rabbit IgG, HRP-
conjugated
Dako, Denmark; P0448
Anti-mouse IgG, HRP-
conjugated
Dianova, Hamburg; 80807
Anti-rabbit IgG, biotinylated Dako, Denmark; P0448
Anti-goat IgG, biotinylated Dako, Denmark; P0449
doi:10.1371/journal.pone.0074412.t003
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for SP-A
*1 (1:500), SP-B
*4 (1:200), SP-C
*5 (1:500), SP-D
*6 (1:500)
at 4uC for 12 hours (displayed in table 2 and 3). Subsequently, the
membrane was washed and the corresponding secondary antibody
(HRP-conjugated) was added in a final dilution of 1:2500 for an
incubation period of 1 hour at room temperature. Positive
immunoreactivity was detected using chemiluminescence (ECL
plus; Amersham-Pharmacia, Uppsala, Sweden) with the IVIS 100
Imaging System (Xenogen Imaging Technologies). The molecular
weights of the detected protein bands were estimated using
standard proteins (Prestained Protein Ladder, Fermentas, St.
Leon-Rot, Germany) ranging from 11 to 170 kDa. To proof for
bacterial contamination all liquor and tissue samples used were
checked for presence of gyrase A using the regarding antibody
[30]. We were unable to find significant amounts of bacterial
contamination in any of the samples.
Immunohistochemistry
For immunohistochemistry, tissue specimens (N=4; 2 female, 2
male cadavers) from brainstem, cerebellum, choroid plexus, pia
mater, pineal gland, pituitary gland and Subventricular cortex
were embedded in paraffin, sectioned (6 mm) and deparaffinized.
Immunohistochemical staining was performed with antibodies to
SP-A
*2, SP-B
*3, SP-C
*5 and SP-D
*7 (displayed in table 2 and 3).
Antigen retrieval was performed by microwave pretreatment for
10 min and nonspecific binding inhibited by incubation with
normal serum (Dako, corresponding to the species, in which the
secondary antibody was produced) 1:5 in Tris buffered saline
(TBS). Each primary antibody was applied overnight at 4uC. The
secondary antibodies were incubated at room temperature for 2 h.
Visualization was achieved with peroxidase-labeled streptavidin-
biotin and diaminobenzidine (DAB) for at least 5 min. After
counterstaining with Mayer’s hematoxylin, the sections were
mounted in Aquatex (Boehringer, Mannheim, Germany). Two
negative control sections were used in each case: one was
incubated with the secondary antibody only, and the other with
the primary antibody only. Sections of human lung served as
positive control. The slides were examined with a Keyence
Biozero BZ8100E microscope.
ELISA – Enzyme-linked immunosorbent assay
Commercially available enzyme-linked immunosorbent assay
kits (USCN, Wuhan, China) were used to quantify the amount of
SP-A (E90890Hu, ELISA Kit for Surfactant Associated Protein
A), SP-B (E91622Hu, ELISA Kit for Surfactant Associated Protein
B), SP-C (E91623Hu, ELISA Kit for Surfactant Associated Protein
C) and SP-D (E91039Hu, ELISA Kit for surfactant-associated
protein D) in samples of cerebrospinal fluid and protein extracts
from human brain tissue. The analysis was performed using a
microplate spectrophotometer (ELISA-reader) at a wavelength of
450 nm and 405 nm for measuring the absorbance. By comparing
with the standard series and the determined values for antigen
concentration (protein concentration), each sample was calculated
as surfactant protein in ng/total protein in mg (ng/mg).
Statistical analysis
After evaluating the values on normal distribution using
Kolmogorov-Smirnov test we performed Mann-Whitney U test
to compare the means among different groups. For the graphical
representations we used box plots showing median value and 50%
interquartile interval for SP-A, SP-B, SP-C, SP-D concentration in
ng/mg for the different groups. The hinge values are 61.5
standard deviation (SD) about the mean value, the data points
indicated by unfilled circles are between 1.5 and 3 SD from the
mean value and outliner data points (.3 SD) are shown as stars.
The number next to the unfilled circle or star indicates to the case
number in the raw data sheet. The PASW SPSS 18 (IBM) for
windowsH software package was used for the statistical analysis. A
p value,0.05 was considered statistically significant.
The analyzed CSF samples were sorted into one out of four
main categories I) autoimmune diseased, II) infection diseased, III)
cerebral infarction, IV) healthy. The medical history of every
subject related to an analyzed CSF sample was studied; thereupon
the CSF sample was categorized in one of these four groups.
CSF samples were included into the ‘autoimmune diseased’
group if the sample was derived from a patient currently diagnosed
with ongoing multiple sclerosis, acute disseminated encephalmo-
myelitis or neuromyelitisoptica.
CSF samples were included into the ‘infection diseased’ – group
if the sample was derived from a patient diagnosed with current
CNS infection of if the suspected diagnosis was ‘encephalitis’,
‘meningitis’ or ‘meningoencephalitis’.
CSF samples were included in the ‘infarction’ group if the
sample was derived from a patient who was at the time diagnosed
with current ‘cerebral infarction’ of either hemorrhagic or
ischemic etiology.
CSF samples were included in the ‘healthy’ group if the sample
was derived from a patient who at the time showed no signs or
findings of CNS-related diseases or was classified as ‘healthy’.
Results
All four SPs are produced by the human central nervous
system
RT-PCR. Since examining m-RNA expression from tissues,
donated post mortem and snap frozen 9–24 hours after death may
have lead to results difficult to interpret, it was decided not to aim
for quantitative PCR analysis. Standard RT-PCR was conducted
to prove the expression of m-RNA corresponding to the surfactant
proteins A, B, C and D only to provide evidence that surfactant
proteins are inherent proteins of the CNS. Real time PCR analysis
of human CNS tissue, obtained from the living individual or
adequate ex vivo testing would provide a much better insight into
the distribution and regulation of the surfactant protein system of
the human CNS. The fact that unaltered, fresh human tissue
specimens, especially samples of the CNS are almost impossible to
obtain (except for encephalopunctures performed for further
diagnosis of brain pathologies) and the lack of controllability of the
post mortal interval were the causes for not conducting real time
PCR instead of standard RT-PCR. Specific cDNA amplification
products (SP-A: 120 bp, SP-B: 239 bp, SP-C: 142 bp and SP-D:
461 bp) were detected in tissue samples (n=7 for each tissue) of
brainstem (BS), cerebellum (Ce), chorioid plexus (CP), subven-
tricular cortex (Ve), pia mater (PM) cerebrospinal fluid (L1, L2,
L3) see Fig. 1A and in pineal gland samples (P1, P2) see Fig. 1B. b-
actin RT-PCR was used as a control PCR, see Fig. (1A), Fig. (1B).
The control PCR was positive and revealed an equal amount for
each tissue in Fig. (1A). In Figure (1B) the expression of m-RNA
for beta actin varied between the investigated samples. The
specimens investigated are tissue samples from lungs and pineal
glands, both organs consist of areas with a high amount of
extracellular matrix and distinct areas with higher cellularity. The
samples we used for molecular analysis were not investigated
microscopically prior to protein extraction or RNA extraction.
Therefore we assume that the specimens we examined using RT-
PCR probably had a different histological composition, which
results in different expression of m-RNA due to a varying relation
of extracellular matrix and cellularity. Base pair values were
The Surfactant Protein System of the Human CNS
PLOS ONE | www.plosone.org 4 September 2013 | Volume 8 | Issue 9 | e74412equivalent to the expected DNA products in comparison to gene
bank data using the designed primers.
Western blot. Protein isolates (n=7 for each tissue) of
brainstem (BS), cerebellum (Ce), choroid plexus (CP) the circle
of Willis (CW), subventricular cortex (Ve), pia mater (PM) and
cerebrospinal fluid (L1, L2) were tested for SP-A, SP-B, SP-C and
SP-D using specific antibodies to each of the SPs, lung (Lu) served
as positive control. Distinct bands were detected for SP-A (pre-
mature form, 66 kDa), SP-B (40 kDa), SP-C (16 kDa) and SP-D
(43 kDa) in each of the samples, see Fig. (2). In the case of SP-C, a
distinct band occurred at 12 kDa in all samples except of
cerebrospinal fluid (L1, L2). Protein isolate from lung tissue was
treated and incubated under the same conditions and showed
distinct bands at the same molecular weight as the CNS-derived
samples.
The hydrophobic surfactant proteins SP-B and SP-C are
produced by cells, which contact the cerebrospinal fluid,
whereas the distribution of the collectin type SPs
aberrates from this pattern
Immunohistochemistry. Paraffin-embedded 6 mm sections
of choroid plexus, cerebral cortex, pineal gland and rhomboid
fossa/brainstem were investigated for presence of SP-A, SP-B, SP-
C and SP-D. Lung tissue was used as positive control and revealed
positive immunoreactivity for all 4 SPs) not shown here, but
already shown in previous work [27,28]. Negative control
(secondary antibody only) was performed and showed no
reactivity.
SP-A is located both diffuse in the cytoplasm and in more
intensively stained granular structures in the ependymal cell layer
in the ventricular region around the hippocampus. Some IR for
SP-A is also present in the subependymal region (Fig. 3, 3-1A).
Similar granular location and some staining in neuronal somatais
evident in the hilus region of the hippocampal formation (Fig. 3, 3-
1B). Strong immunoreactivity for SP-A is expressed by the apical
part of the outer layer of the choroid plexus (Fig. 3, 3-1C) and
somata of pyramid cells of the dentate gyrus (Fig. 3, 3-1D). The
strong somatic staining in these pyramid cells is seen at higher
magnification in the insert of 3-1D. In the pineal organ SP-A-IR is
present in some pinealocytes and the interlobular structures
around the large groups of pinealocytes (Fig. 3, 3-1E). In a
horizontal section perpendicular to the brain stem axis of Meynert
in the region of the lateral and medial vestibular nucleus and the
nucleus of the abducens nerve, some cells, presumably neurons,
display somatic immunoreactivity for SP-A (Fig. 3, 3-1F).
SP-B is present in the apical part the ependymal cell layer in the
ventricular region around the hippocampus. The basal region is
less strongly stained compared to the apical but also immunore-
active. IR for SP-B is also found in the subependymal region in
both granular and fibrose structures (Fig. 3, 3-2A). Diffuse staining
is evident in neuronal somata of the hippocampal hilus region
(Fig. 3, 3-2B). Strong immunoreactivity for SP-B is expressed by
the apical and basal part of the outer layer of the choroid plexus
(Fig. 3, 3-2C) and somata of pyramid cells of the dentate gyrus
Figure 1. RT-PCR analysis of human brain. Detection of SP-A, SP-B, SP-C and SP-D in A) tissue specimens of brainstem (BS), cerebellum (Ce),
choroid plexus (CP), subventricular cortex (Ve), pia mater (PM) and cerebrospinal fluid (L1, L2, L3) and B) in pineal gland (P1, P2). DEPC-H2O served as
negative control (2), RNA-extract from lung tissue was used as positive control (+), molecular size was estimated using a molecular marker (M).
doi:10.1371/journal.pone.0074412.g001
Figure 2. Western blot analysis of surfactant proteins. Detection
of SP-A, SP-B, SP-C and SP-D after SDS gel electrophoresis in protein
isolates of brainstem (BS), cerebellum (Ce), choroid plexus (CP) the circle
of Willis (CW), subventricular cortex (Ve), leptomeninx (PM) and
cerebrospinal fluid (L1, L2), Lung (Lu) served as positive control.
doi:10.1371/journal.pone.0074412.g002
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PLOS ONE | www.plosone.org 5 September 2013 | Volume 8 | Issue 9 | e74412Figure 3. Immunhistochemistry of surfactant proteins A, B, C and D. Figure 3-1: Immunohistochemistry of SP-A: Detection of surfactant
protein A in the CNS by means of immunohistochemistry. Sections from the ventricles [A], the hilum region of the hippocampus [B], choroid plexus
[C], the dentate gyrus [D], pineal gland [E] and medulla oblongata [F] were analyzed. Red staining indicates SP-A occurrence. Insets in the figures
show magnifications for the respective tissue. Control sections (secondary antibody only) were negative (unstained) for each tissue. Scale bars:
50 mm. Figure 3-2: Immunohistochemistry of SP-B: Detection of surfactant protein B in the CNS by means of immunohistochemistry. Sections from
The Surfactant Protein System of the Human CNS
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pinealocytes in both diffuse and granular form (Fig. 3, 3-2E). In
a horizontal section perpendicular to the brain stem axis of
Meynert in the region of the lateral and medial vestibular nucleus
and the nucleus of the abducens nerve magnocellular neurons
exert somatic immunoreactivity for SP-B (Fig. 3, 3-2F).
SP-C is present in the apical and basal part the ependymal cell
layer in the ventricular region around the hippocampus (Fig. 3, 3-
3A). Cytoplasmic staining is found in neuronal somata of the
hippocampal hilus region (Fig. 3, 3-3B). Strong immunoreactivity
for SP-C is expressed by the apical and basal part of the outer
layer of the choroid plexus (Fig. 3, 3-3C). Only faint signals are
seen in the somata of dentate gyrus pyramid cells (Fig. 3, 3-3D). In
the pineal organ SP-C-IR is present in pinealocytes in both diffuse
and granular form (Fig. 3, 3-3E). In a horizontal section
perpendicular to the brain stem axis of Meynert around the
nucleus of the abducens nerve in close proximity to abducens
nerve fibers some magnocellular neurons exert somatic immuno-
reactivity for SP-C (Fig. 3, 3-3F).
Strong immunoreactivity for SP-C is found, among others, in
the region of the fossa rhomboidea (Fig. 3, 3–5A, C). Protein
plaques, neuromelanin granules and degenerated cellular struc-
tures were positive for SP-C.
SP-D is present in the apical part the ependymal cell layer in the
ventricular region around the hippocampus (Fig. 3, 3–4A/C).
Endothelial staining of large vessels is found in the hippocampal
hilus region (Fig. 3, 3-4B). Strong immunoreactivity for SP-D is
present in the somata of dentate gyrus small pyramid cells (Fig. 3,
3-4D). Immunoreactivity for SP-D is strongly expressed by the
apical part of the outer layer of the choroid plexus, the basal parts
is less strongly stained (Fig. 3, 3-4E). In the pineal organ SP-D-IR
is present in pinealocytes in both diffuse and granular form (Fig. 3,
3-4F).
Quantification of surfactant proteins A, B, C and D in the
CSF – ELISA and subsequent statistical analysis
Autoimmune diseased vs. non autoimmune diseased vs.
healthy (Figure 4, 4-1, Table 4): Surfactant protein A. A
total of 64 samples were analyzed. 18 (11 female, 7 male) CSF
samples derived from patients suffering from a CNS disease with
autoimmune etiology were compared to 18 (5 female, 13 male)
samples derived from patients suffering from a CNS condition
with non-autoimmune etiology and 28 (10 female, 18 male)
samples derived from healthy subjects.
The level of SP-A concentration in CSF from patients with
autoimmune CNS disease was statistically significantly decreased
(p=0.01) compared to the level of SP-A concentration in the
healthy group.
Surfactant protein B. A total of 69 samples were analyzed.
20 (11 female, 9 male) CSF samples derived from patients suffering
from a CNS disease with autoimmune etiology were compared to
21 (5 female, 16 male) samples derived from patients suffering
from a CNS condition with non-autoimmune etiology and 28 (10
female, 18 male) samples derived from healthy subjects.
Statistical analysis revealed that the level of SP-B in CSF from
patients with an autoimmune CNS disease was significantly
decreased (p=0.015) compared to the level of SP-B in the healthy
group.
Surfactant Protein C. A total of 73 samples were analyzed.
20 (11 female, 9 male) CSF samples derived from patients suffering
from a CNS disease with autoimmune etiology were compared to
25 (7 female, 18 male) samples derived from patients suffering
from a CNS condition with non-autoimmune etiology and 28 (10
female, 18 male) samples derived from healthy subjects.
The level of SP-C in CSF from patients with an autoimmune
CNS disease was comparable to the level of SP-C in the healthy
group (p=0.415).
Surfactant Protein D. A total of 74 samples were analyzed.
20 (11 female, 9 male) CSF samples derived from patients suffering
from a CNS disease with autoimmune etiology were compared to
26 samples (7 female, 19 male) derived from patients suffering
from a CNS condition with non-autoimmune etiology and 28 (10
female, 18 male) samples derived from healthy subjects.
The level of SP-D in CSF from patients with an autoimmune
CNS disease was decreased in a statistically significant manner
(p=0.01) compared to the level of SP-D in the healthy group.
Cerebral infarction vs. non-infarction diseased vs.
healthy (Figure 4, 4-2, Table 4): Surfactant Protein A. A
total of 64 samples were analyzed. 5 (2 female, 3 male) CSF
samples derived from patients who had suffered a cerebral
infarction were compared to 31 (16 female, 15 male) samples
derived from patients suffering from a CNS condition not related
to cerebral infarction and 28 (10 female, 18 male) samples derived
from healthy subjects.
The level of SP-A in CSF from patients with cerebral infarction
was slightly decreased, but did not reach statistical significance
(p=0.083) compared to the level of SP-A in the healthy group.
Surfactant Protein B. A total of 71 samples were analyzed. 7
(2 female, 5 male) CSF samples derived from patients who had
suffered a cerebral infarction were compared to 36 (19 female, 17
male) samples derived from patients suffering from a CNS
condition not related to cerebral infarction and 28 (10 female,
18 male) samples derived from healthy subjects. The level of SP-B
in CSF from patients with cerebral infarction was statistically
significantly increased (p=0.002) in comparison to the level of SP-
B in the healthy group.
Surfactant Protein C. A total of 73 samples were analyzed. 7
(2 female, 5 male) CSF samples derived from patients who had
the ventricles [A], the hilum region of the hippocampus [B], choroid plexus [C], the dentate gyrus [D], pineal gland [E] and medulla oblongata [F] were
analyzed. Red staining indicates SP-B occurrence. Insets in the figures show magnifications for the respective tissue. Control sections (secondary
antibody only) were negative (unstained) for each tissue. Scale bars: 50 mm. Figure 3-3: Immunohistochemistry of SP-C: Detection of surfactant
protein C in the CNS by means of immunohistochemistry. Sections from the ventricles [A], the hilum region of the hippocampus [B], choroid plexus
[C] the dentate gyrus [D], pineal gland [E] and medulla oblongata [F] were analyzed. Red staining indicates SP-C occurrence. Insets in the figures show
magnifications for the respective tissue. Control sections (secondary antibody only) were negative (unstained) for each tissue. Scale bars: 50 mm.
Figure 3-4: Immunohistochemistry of SP-D: Detection of surfactant protein D in the CNS by means of immunohistochemistry. Sections from the
ventricles [A, C], the hilum region of the hippocampus [B] and near the dentate gyrus [D], choroid plexus [E], and pineal gland [F] were analyzed. Red
staining indicates SP-D occurrence. Inserts in the figures show magnifications for the respective tissue. Control sections (secondary antibody only)
were negative (unstained) for each tissue. Scale bars: 50 mm. Figure 3-5: Immunohistochemistry of SP-C plaques: Detection of surfactant protein C in
the CNS by means of immunohistochemistry. Sections from fossa rhomboidea stained [A–C], and unstained [C–D] for SP-C were analyzed. Red
staining indicates SP-C occurrence. Insets in the figures show magnifications for the respective tissue. Control sections (secondary antibody only)
were negative (unstained) for each tissue. Arrows indicate the possible plaque sites, neuromelanin granules and possibly degenerated neurons. Scale
bars: 50 mm.
doi:10.1371/journal.pone.0074412.g003
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CNS. Figure 4-1: ELISA quantification of surfactant proteins A, B, C and D from autoimmune diseased vs. non-autoimmune diseased vs. healthy. ELISA
derived from the following samples: cerebrospinal fluid from different patients, with non-autoimmune diseased, with autoimmune diseased and
healthy. The protein concentration is expressed in ng/mg. (P#0.05). Figure 4-2: ELISA quantification of surfactant proteins A, B, C and D from cerebral
infarction vs. non-infarction diseased vs. healthy. ELISA derived from the following samples: cerebrospinal fluid from different patients, with non-
infarction diseased, with cerebral infarction and healthy. The protein concentration is expressed in ng/mg. (P#0.05). Figure 4-3: ELISA quantification
of surfactant proteins A, B, C and D from cerebral infection vs. non-infection diseased vs. healthy. ELISA derived from the following samples:
cerebrospinal fluid from different patients, with non-infectious diseased, with infectious diseased and healthy. The protein concentration is expressed
in ng/mg. (P#0.05).
doi:10.1371/journal.pone.0074412.g004
Table 4. Differences of SP concentration in CSF: diseased groups compared to the healthy control group. Legend: qq increased,
p,0.05, q increased, p.0.05 QQ decreased, p,0.05 Q decreased, p.0.05= no difference.
Autoimmune vs. healthy cerebral infarction vs. healthy cerebral infection vs. healthy
SP-A qq Q QQ
SP-B QQ qq q
SP-C q = Q
SP-D QQ QQ QQ
doi:10.1371/journal.pone.0074412.t004
The Surfactant Protein System of the Human CNS
PLOS ONE | www.plosone.org 8 September 2013 | Volume 8 | Issue 9 | e74412suffered a cerebral infarction were compared to 38 (19 female, 19
male) samples derived from patients suffering from a CNS
condition not related to cerebral infarction and 28 (10 female,
18 male) samples derived from healthy subjects. The level of SP-C
in CSF from patients with cerebral infarction showed no difference
(p=0.967) compared to the level of SP-C in the healthy group.
Surfactant Protein D. A total of 73 samples were analyzed. 7
(2 female, 5 male) CSF samples derived from patients who had
suffered a cerebral infarction were compared to 39 (19 female, 20
male) samples derived from patients suffering from a CNS
condition not related to cerebral infarction and 28 (10 female,
18 male) samples derived from healthy subjects. The level of SP-D
in CSF from patients with cerebral infarction was statistically
significantly decreased compared to the level of SP-D in the
healthy group (p=0.012).
Cerebral infection vs. non-infection diseased vs. healthy
(Figure 4, 4-3, Table 4): Surfactant Protein A. A total of 64
samples were analyzed. 9 (3 female, 6 male) CSF samples derived
from patients diagnosed at the time with an infectious disease of
the CNS were compared to 27 (13 female, 14 male) samples
derived from patients suffering from a different disorder of the
CNS than infection and 28 (10 female, 18 male) samples derived
from healthy subjects. The level of SP-A in CSF from patients with
a CNS infection was statistically significantly decreased (p=0.044)
compared to the level of SP-A in the healthy group.
Surfactant Protein B. A total of 69 samples were analyzed.
10 (3 female, 7 male) CSF samples derived from patients
diagnosed at the time with an infectious disease of the CNS were
compared to 31 (13 female, 17 male) samples derived from
patients suffering from a different disorder of the CNS than
infection and 28 (10 female, 18 male) samples derived from
healthy subjects.
The level of SP-B in CSF from patients with a CNS infection
was slightly increased, but did not reach statistical significance
compared to the level of SP-A in the healthy group (p=0.083).
Surfactant Protein C. A total of 73 samples were analyzed.
11 (3 female, 8 male) CSF samples derived from patients
diagnosed at the time with an infectious disease of the CNS were
compared to 34 (14 female, 20 male) samples derived from
patients suffering from a different disorder of the CNS than
infection and 28 (10 female, 18 male) samples derived from
healthy subjects. The level of SP-C in CSF from patients with a
CNS infection was slightly decreased, but did not reach statistical
significance (p=0.072) compared to the level of SP-C in the
healthy group.
Surfactant Protein D. A total of 74 samples were analyzed.
12 (4 female, 8 male) CSF samples derived from patients
diagnosed at the time with an infectious disease of the CNS were
compared to 34 (14 female, 20 male) samples derived from
patients suffering from a different disorder of the CNS than
infection and 28 (10 female, 18 male) samples derived from
healthy subjects. The level of SP-D in CSF from patients with a
CNS infection was statistically significantly decreased (p=0.001)
in comparison to the level of SP-D in the healthy group.
Quantification of surfactant proteins A, B, C and D in
human brain tissue – ELISA
ELISA was performed with protein extracts from subventricular
cortex, brainstem, cerebellum and choroid plexus from body
donors with comparable postmortal intervals. The surfactant
protein concentration in brain tissue (except the choroid plexus)
was measured to be approximately twenty five percent of the
surfactant protein concentration in the lungs. The surfactant
protein concentrations of the cerebellum, the subventricular cortex
and the brainstem were in equal range, whereas the tissue
concentration of all SPs in the choroid plexus was approximately
twofold higher compared to the concentration in brainstem,
cerebellum and subventricular cortex.
Discussion
By use of RT-PCR we were able to verify the intrinsic
production of messenger RNA for all investigated SPs by the
central nervous system. The fact that we found mRNA for the SPs
in the cerebrospinal fluid is unexpected. We hypothesize that the
mRNA we found is a result of the cell damage due to the trauma
of the lumbar puncture, which always leads to limited destruction
of cells (especially meningeal cells) in the area of the puncture. The
cell damage results in the liberation of intracellular components
like proteins and mRNA. We address this as the reason for the
detection of SP-specific mRNA in the CSF. The results of Western
blot and immunohistochemical analysis confirm our findings on
protein level. Based on proof of both the production of SPs in the
human CNS and the expression of SP-specific mRNA, our study
reveals the existence of surfactant proteins as inherent proteins of
the CNS.
In the case of SP-C, the antibody used detected premature
forms of the proteins at 12 kDa only in the non-CSF tissue. This
issue is well known and a consequence of an intense posttrans-
lational processing of the SPs. We therefore conclude that mature
SP-C does not play an important role in host defense or
amelioration of inflammation in CNS diseases.
The collectin-type SPs A and D showed immunoreactivity in
the tissue surrounding the microvasculature of the brain paren-
chyma, the capillaries of choroid plexus stroma and the small
vessels at the base of the pineal gland. Both proteins were detected
in the vascular layers (with the exception of the tunica intima) as
well as in the adjacent brain tissue. Their volumetric abundance
between the blood milieu of the cerebral vessels and the brain
tissue, especially at the level of the glia limitans (formed by
astrocytic endfeet) and the perivascular Virchow-Robin space,
resembling the microanatomical correlate of the blood-brain
barrier, indicates a participation in this convolute of CNS-
protective mechanisms. In lung, SP-A and SP-D are known to
be antimicrobially active proteins of the alveolar surface. They are
localized in the surfactant layer lining the alveolar surface as well
as within the apical portion of the type II alveolar epithelial cells.
One of their tasks is to bind microbial invaders like Pseudomonas
aeruginosa or Staphylococcus aureus, to mediate their elimination
via direct bactericidal effects or indirectly by means of opsoniza-
tion and subsequent phagocytosis by macrophages [31]. Consid-
ering our findings and the well-known functions of SP-A and SP-
D, we hypothesize that SP-A and SP-D are pathogen-binding
proteins that prevent the invasion of the CNS by microbial
invaders circulating with the blood stream. The collectin-type SPs
may directly kill extravasating bacteria on their way into the brain
tissue. They could furthermore facilitate the elimination of
invading microbes by opsonization via their carbohydrate
recognition domain and following binding to surveilling perivas-
cular microglia. Finally, in case of a CNS infection, they may
trigger the shift from an anti-inflammatory to a pro-inflammatory
milieu in the CNS by binding to resting microglia, with subsequent
activation and production of pro-inflammatory mediators [5].
Another group of antimicrobial peptides, the human b-defensins 1
and 2, is expressed by cells at both sites, the ’’air lung barrier‘‘ [32]
and the blood brain barrier [33]. Human b-defensin 1 and 2 are
produced by epithelial cells at different sites of the body, e.g. in the
intestinal mucosa, the female reproductive tract and the lungs.
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body by directly killing the pathogens (perforation of bacterial
walls) and mediate the uptake of antigens by binding to specific
receptors on phagocytotic cells [34]. Another human b-defensin,
DEFB123, has been shown to bind bacterial lipopolysaccharides
and prevent the lethal consequences of sepsis in a mouse model
[35]. The similar functions and the resemblance in the distribution
patterns of the two systems – the collectin-type SPs and the human
b-defensins, especially at anatomical-physiological barriers in
different tissues, underlines the possible importance of SP-A and
SP-D as players in innate immunity at the BBB.
The lipophilic SPs show immunoreactivity in the epithelial layer
of the choroid plexus, in the ependymal cells lining the four
ventricles of the brain and in the ependyma of the spinal channel.
The choroid plexus and the ependymal cells of the ventricles are
the main production site of the cerebrospinal fluid [36,37]. The
production, flow and resorption of CSF have to be closely
regulated. A decreased production, an impaired flow or an
insufficient resorption of CSF rapidly lead to altered intracranial
pressure, thus resulting in severely neurological conditions such as
spontaneous intracranial hypotension, idiopathic intracranial
hypertension and normal pressure hydrocephalus [38]. Neither
of the underlying pathomechanisms for these conditions is well
understood.
The function and physiological importance of SP-B and SP-C
has been studied in the lungs, the auditive tube, the tear fluid and
the lacrimal system among other sites [18,28,39,40]. Both proteins
are crucial for the formation and stability of surface-active
monolayers and contribute to lowering the surface tension, thus
preventing the collapse of the alveoli at the end of expiration [41].
They furthermore regulate the permeability of surfactant phos-
pholipid membranes [20]. Inherited defects of SP-B and SP-C lead
to respiratory failure and interstitial lung disease in early childhood
[42]. Considering their ability to decrease surface tension,
modulate the permeability of biomembranes and lower the
viscosity of phospholipid layers [43], we assume that SP-B and
SP-C are essential for the continuous secretion of CSF, the
maintenance of its rheological properties and correct drainage into
the arachnoid villi of the cerebral venous sinuses. We furthermore
hypothesize that disturbances of the metabolism of SP-B and SP-C
may be of pathogenic importance for conditions like spontaneous
intracranial hypotension, idiopathic intracranial hypertension and
normal pressure hydrocephalus. In our analysis of immunohisto-
chemistry of surfactant protein C, we found plaque-like structures
in many areas of the brain. The staining of SP-C is specific and we
propose that SP-C may play an interesting role in the development
of plaques like those found in the brains of Alzheimer’s patients. It
is known that SP-C forms amyloid structures (‘‘plaques’’) as a
result of misfolding of the proteins [44,45]. Comparing the plaque
images from other publications with the SP-C immunoreactivity
described here, we conclude that what we have here is the first
positive evidence for the presence of SP-C in human brain plaques
[46,47]. In this context it is assumed that amyloid structures exist
due to failure of the clearance system via the glymphatic pathway.
The failure of this clearance system contributes to amyloid plaque
deposition and Alzheimer’s disease progression [48].
The choroid plexus and the ventricular ependyma also produce
phospholipid transfer protein, another protein participating in the
formation of the surfactant layer in the lungs [49,50]. After this
initial description of a protein at the blood-cerebrospinal fluid
barrier, which plays an important role for the decrease of surface
tension within the alveoli, we now report the existence of a second
functionally related protein system at this particular location in the
CNS – the lipophilic SPs. We understand the abundance of both
systems at the blood-CSF barrier as a strong indicator for the
hypothesis that surface-active proteins of the lung are also utilized
to maintain the rheological properties of cerebrospinal fluid in
order to perpetuate a physiological CSF flow.
The concentration of the collectin-type SPs in CSF samples
from patients with autoimmune diseases, infectious conditions and
CNS infarctions was significantly lower compared to samples
derived from healthy subjects. It thus appears that both proteins
are involved in inflammatory processes in the CNS. Considering
the known functions of these proteins, we assume their contribu-
tion in the local immune response. SP-A and SP-D are involved in
the clearance of pathogens and apoptotic polymorph nuclear
neutrophils [51,52].
Polymorph nuclear neutrophils are among the first wave of
innate immune cells at inflammation sites, they release a whole
arsenal of anti-microbial molecules and their survival is closely
regulated to prevent tissue damage caused by excessive neutrophil
activity [53]. The collectin-type SPs may be involved in the
elimination of both exhausted neutrophils and microbial invaders
in the CNS. Similar to the situation in lung they may bind to the
pathogen or the apoptotic cell and subsequently mediate the
phagocytosis via CD91 and calreticulin [54]. It has been shown
that SP-A and SP-D are effective opsonins for apoptotic cells. Like
mannose-binding lectin (MBL) and the complement factor C1q,
SP-A and SP-D label cells that have undergone programmed cell
death for macrophages to facilitate their phagocytosis [55,56].
As a consequence of this, the collectin-type SPs may be removed
from the CSF of patients with inflammatory CNS conditions like
infarctions, infections or autoimmune diseases during the phago-
cytosis of (SP-) opsonized targets.
The concentration of SP-B in CSF samples from patients with
autoimmune CNS conditions was significantly lower compared to
samples from healthy subjects. By contrast, the SP-B concentration
in CSF samples from patients with infections and infarctions of the
CNS was significantly higher than the concentration in samples
from the healthy group.
The phenomenon of high SP-B concentration in the CSF of
patients with inflammation of non-autoimmune etiology and low
SP-B concentration in the CSF of patients with autoimmune
etiology probably has different underlying mechanisms.
SP-B possesses anti-inflammatory properties and has the
potential to reverse inflammation in the lungs [21]. It also inhibits
endotoxin-induced lung inflammation [57]. The concentration of
SP-B in amniotic fluid of patients with intra-amniotic infection is
significantly increased compared to that of healthy pregnant
women [58].
Consistent with these findings, we propose that SP-B is
upregulated during exogenously induced inflammation in order
to limit and counterbalance the detrimental effects caused by the
host’s immune system. Specifically, we hypothesize that SP-B is a
protein of the CSF, constitutively produced by the choroid plexus
to facilitate CSF flow with a reactively increased production rate in
case of pathogen-induced or ischemically triggered, acute
neuroinflammation.
The decreased concentration of SP-B in CSF samples from
patients with autoimmune CNS conditions may be the conse-
quence of a continuous depletion of SP-B due to the chronicity of
autoimmune diseases. Autoimmune CNS conditions like multiple
sclerosis are coupled with permanent inflammation, influx of
immune cells and cell death in the CNS [59]. The persistent
chronic inflammation may lead to a high consumption of SP-B,
resulting in a functional insufficiency of the choroid plexus and the
ependymal cells to produce SP-B, finally leading to a decreased
concentration of SP-B in the CSF. The involvement of SP-B in
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knowledge. A thorough review of the literature on this issue
revealed no evidence of studies focusing on lipophilic SPs in
autoimmune diseases.
We were able to detect SP-C in all of the investigated CSF
samples, but there was no difference in the concentration of SP-C
between the different groups. We therefore conclude that mature
SP-C does not play an important role in host defense or
amelioration of inflammation in CNS diseases. Western blot
analysis did not reveal the existence of the 12 kDa premature form
of SP-C in the CSF. It is therefore conceivable that this premature
form may be regulated differently in the investigated groups of
CNS conditions, but the ELISA system we used may also not be
capable of detecting the 12 kDa form.
Conclusion
The ‘pulmonary’ surfactant proteins are also inherent proteins
of the human CNS. The collectin-like SPs – SP-A and SP-D show
a similar distribution pattern in the CNS, which varies from the
distribution pattern of the hydrophobic SPs SP-B and SP-C. Their
expression at different locations in the CNS indicates participation
of the SPs in processes like host defense and maintenance of CSF
flow, but the dimension of their importance and their exact
function must be investigated in subsequent studies.
The concentration of surfactant proteins in the CSF of healthy
subjects deviates from patients with CNS conditions of autoim-
mune, ischemic and infectious etiology. This also speaks for the
importance of the SPs in processes such as fine-tuning of
inflammation and host defense. It is still not clear which cells
are exactly responsible for production of the collectin-type SPs
within the CNS. This remains to be investigated prior to more
functional studies.
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